S1256 Gut Permeability and Stool Frequency Are Correlating in Diarrhea-Predominant Irritable Bowel Syndrome

2009 ◽  
Vol 136 (5) ◽  
pp. A-223
Author(s):  
Krisztina Gecse ◽  
Richárd Róka ◽  
Emese Séra ◽  
András Rosztóczy ◽  
Ferenc Izbeki ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Stool Frequency ◽  
Gut Permeability ◽  
Irritable Bowel

Gut permeability in patients with irritable bowel syndrome and inactive ulcerative colitis

2009 ◽  
Vol 47 (05) ◽  
Author(s):  
K Gecse ◽  
R Róka ◽  
T Séra ◽  
A Annaházi ◽  
A Rosztóczy ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Gut Permeability ◽  
Irritable Bowel

scholarly journals Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine

2011 ◽  
Vol 48 (1) ◽  
pp. 36-40 ◽  
Author(s):  
Mauro Bafutto ◽  
José Roberto de Almeida ◽  
Nayle Vilela Leite ◽  
Enio Chaves Oliveira ◽  
Salustiano Gabriel-Neto ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Symptom Score ◽  
Stool Frequency ◽  
Total Symptom Score ◽  
Stool Consistency ◽  
Mucosal Inflammation ◽  
Irritable Bowel Syndrome Group ◽  
Irritable Bowel ◽  
Postinfectious Irritable Bowel Syndrome

CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown. OBJECTIVE: To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. METHODS: Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4). RESULTS: Postinfectious irritable bowel syndrome group presented a statistically significant reduction of the total symptom score (P<0.0001). The stool frequency was significantly reduced (P<0.0001), and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distension were significantly reduced (P<0.0001). Noninfective irritable bowel syndrome group presented a statistically significant reduction of total symptom score (P<0.0001). Also, the stool frequency was significantly reduced (P<0.0001) and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distention were significantly reduced (P<0.0001). There was no statistical difference between postinfectious irritable bowel syndrome group and noninfective irritable bowel syndrome group on total symptom score results at 30th day of therapy with mesalazine 800 mg 3 times a day. (P = 0.13). CONCLUSION: Mesalazine reduced key symptoms of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients.

scholarly journals Irritable Bowel Syndrome and Gluten-Related Disorders

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1117 ◽  
Author(s):  
Paolo Usai-Satta ◽  
Gabrio Bassotti ◽  
Massimo Bellini ◽  
Francesco Oppia ◽  
Mariantonia Lai ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Celiac Disease ◽  
The Other ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Gut Permeability ◽  
Online Search ◽  
Systematic Screening ◽  
Wheat Sensitivity ◽  
Irritable Bowel

Background: Irritable bowel syndrome (IBS) is frequently associated with celiac disease (CD) and nonceliac gluten/wheat sensitivity (NCGS/NCWS), but epidemiological and pathophysiological aspects are still unclear. Furthermore, a gluten-free diet (GFD) can positively influence IBS symptoms. Methods: A comprehensive online search for IBS related to CD, NCGS and GFD was made using the Pubmed, Medline and Cochrane databases. Results: Although a systematic screening for CD in IBS is not recommended, CD prevalence can be increased in diarrhea-predominant IBS patients. On the other hand, IBS symptoms can be persistent in treated CD patients, and their prevalence tends to decrease on a GFD. IBS symptoms may overlap and be similar to those associated to nonceliac gluten and/or wheat sensitivity. Increased gut permeability could explain the gluten/wheat effects in IBS patients. Finally, a GFD could improve symptoms in a subgroup of IBS patients. Conclusions: The possible interplay between IBS and gluten-related disorders represents a scientifically and clinically challenging issue. Further studies are needed to confirm these data and better clarify the involved pathophysiological mechanisms.

scholarly journals Increased Gut Permeability in First-degree Relatives of Children with Irritable Bowel Syndrome or Functional Abdominal Pain

2020 ◽  
Vol 18 (2) ◽  
pp. 375-384.e1 ◽  
Author(s):  
Mark McOmber ◽  
Danny Rafati ◽  
Kevin Cain ◽  
Sridevi Devaraj ◽  
Erica M. Weidler ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Gut Permeability ◽  
Functional Abdominal Pain ◽  
First Degree Relatives ◽  
Irritable Bowel

scholarly journals GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome

Cell Genomics ◽  
2021 ◽  
Vol 1 (3) ◽  
pp. 100069
Author(s):  
Ferdinando Bonfiglio ◽  
Xingrong Liu ◽  
Christopher Smillie ◽  
Anita Pandit ◽  
Alexander Kurilshikov ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Motility ◽  
Stool Frequency ◽  
Irritable Bowel

scholarly journals Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis

2017 ◽  
Vol 10 (3) ◽  
pp. 311-322 ◽  
Author(s):  
Pere Clavé ◽  
Jan Tack
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Pooled Analysis ◽  
Stool Frequency ◽  
Global Response ◽  
Intention To Treat ◽  
Therapeutic Benefits ◽  
Irritable Bowel ◽  
To Receive ◽  
Significant Therapeutic Effect

Background: Otilonium bromide (OB) is a spasmolytic agent acting as an L-type calcium channel antagonist in intestinal and colonic smooth muscle cells (SMCs). We analyzed three independent clinical trials with homogeneous design on patients with irritable bowel syndrome (IBS). After 2 weeks receiving placebo, patients were randomized to receive OB (3 × 40 mg daily) or placebo for 15 weeks. We aimed to perform a pooled analysis of the data from these homogeneous clinical trials to evaluate the efficacy of OB treatment on symptoms and global response of patients. Methods: A total of 883 patients with IBS (69.8% women, mean age 46.2 years, 43.8% mixed type) were included, 442 treated with OB and 441 with placebo. The efficacy results from the three studies at weeks 5, 10 and 15 were pooled in an intention-to-treat (ITT) strategy, analyzed with a logistic regression model and described by forest plots. Results: Despite a placebo effect in all efficacy variables, a significant therapeutic effect of OB was observed at weeks 10 and 15 with reference to: (a) intensity and frequency of abdominal pain; (b) rate of responders as evaluated by patients (71.8% at week 10 and 77.2% at week 15); (c) severity of bloating; (d) rate of responders as evaluated by physicians (55% at week 10 and 63.9% at week 15). No significant OB effect was observed in stool frequency and consistency. Conclusions: OB is more effective than placebo in IBS treatment. Therapeutic benefits are significant after 10 weeks and are maximal after 15 weeks of treatment.

Sign in / Sign up

Export Citation Format

Share Document